

CEDARS-SINAI®

SMIDT HEART INSTITUTE

Does Occupation Affect Outcome Following Heart Transplantation?

Tina Kao, BSN, RN, Angela Velleca, BSN, RN, Jignesh Patel, MD, PhD, Michelle Kittleson, MD, PhD, Lawrence Czer, MD, Sadia Dimbil, BS, Ryan Levine, BS, Alison Sanford, Undergrad, Brenda Kearney, RN, Evan Kransdorf, MD, PhD, David Chang, MD, <u>Kristine Norland, RN</u>, Jon Kobashigawa, MD.

Cedars-Sinai SMIDT Heart Institute, Los Angeles, CA

Abstract

Background: Among many social factors affecting outcome after heart transplantation (HTx), occupation (OCC) may be important for compliance as it may impact infection, rejection and survival.

Methods: Between 2007-2012 we assessed 283 HTx outcomes according to OCC. These included manual labor (blue-collar) (n=117), white-collar (n=154), and military (n=12). Specific OCC subcategories were selected based on larger numbers and included teachers(n=11), physicians(n=24) and business owners (n=13). We assessed 1-yr freedom from rejection and infection, 5-yr survival, 5-yr freedom from cardiac allograft vasculopathy(CAV) (angiographic stenosis \geq 30%), and 5-yr freedom from nonfatal major adverse cardiac events (NF-MACE: myocardial infarction, new congestive heart failure, percutaneous coronary intervention, implantable cardioverter defibrillator/pacemaker implant, stroke). Compliance was assessed (cancelled or no-show appointments, lost to followup).

Demographics

Demographic	Blue-Collar Workers (n=117)	White- Collar Workers (n=154)	Military Personnel (n=12)	P- Value
Mean Recipient Age, Years ± SD	52.9 ± 12.3	56.7 ± 11.5	59.3 ± 14.2	0.004
Mean Donor Age, Years ± SD	33.0 ± 12.6	35.7 ± 12.7	38.3 ± 10.4	0.129
Body Mass Index, Mean ± SD	25.1 ± 4.9	25.7 ± 4.8	28.4 ± 4.6	0.084
Female (%)	12.9%	35.1%	0.0%	< 0.001
Previous Pregnancy in Females (%)	73.3%	72.2%		0.932
Ischemic Time, Mean Mins ± SD	201.1 ± 58.2	184.1 ± 65.7	202.8 ± 52.3	0.081
Primary Reason for Transplant, Underlying Diagnosis of Coronary Artery Disease (%)	35.9%	47.4%	75.0%	0.014
Status 1 at Transplant (%)	70.9%	64.9%	50.0%	0.263
Cytomegalovirus Mismatch (%)	15.7%	25.8%	40.0%	0.062
Diabetes Mellitus (%)	41.6%	36.2%	50.0%	0.513
Treated Hypertension (%)	62.6%	53.6^	90.0%	0.045
Insertion of Mechanical Circulatory Support Device (%)	39.5%	19.0%	33.3%	0.001
Prior Blood Transfusion (%)	38.6%	37.4%	18.2%	0.408
Pre-Transplant PRA≥10% (%)	30.7%	33.1%	25.0%	0.803
Pre-Transplant Creatinine, Mean ± SD	1.5 ± 1.3	1.5 ± 1.9	1.4 ± 0.3	0.930
ATG Induction Therapy (%)	49.5%	52.4%	50.0%	0.902

Outcomes

<u>Results</u>: There was no significant difference in 1-yr rejection, 5-yr survival or freedom from CAV among all groups. Numerically, military personnel did better in all outcomes except 5-yr freedom from NF-MACE. Teachers and business owners had a significantly reduced 5-yr freedom from NF-MACE vs. physicians (p=0.023, see table). There was no difference in compliance between professions.

<u>Conclusion</u>: OCC appears not to affect most outcomes or compliance following HTx. Military personnel may have better outcome. Further investigation into teachers and business owners having less freedom from NF-MACE is warranted but other variables may be important.

Background

• Among many social factors affecting outcome after heart transplantation (HTx), occupation (OCC) may be important for compliance as it may impact infection, rejection and survival.

Purpose

• To assess whether occupation affects outcomes after heart transplantation.

Methods

- Between 2007-2012 we assessed 283 HTx outcomes according to OCC.
- These included manual labor (blue-collar) (n=117), white-collar (n=154), and military (n=12).
- Specific OCC subcategories were selected based on larger numbers and included teachers(n=11), physicians(n=24) and

|--|--|

Endpoints	Blue-Collar Workers (n=117)	White- Collar Workers (n=154)	Military Personnel (n=12)	P- Value
% Non-Compliance	24.8%	26.0%	8.3%	0.899
1-Year Freedom from Any-Treated Rejection	87.1%	86.4%	91.7%	0.874
1-Year Freedom from Acute Cellular Rejection	92.3%	93.5%	100.0%	0.575
1-Year Freedom from Antibody- Mediated Rejection	98.3%	96.1%	100.0%	0.462
1-Year Freedom from Infection	53.8%	55.0%	75.0%	0.405
5-Year Survival	75.2%	79.9%	91.7%	0.305
5-Year Freedom from CAV	81.2%	81.8%	83.3%	0.883
5-Year Freedom from NF-MACE	81.7%	86.4%	75.0%	0.380

Endpoints	Teachers (n=11)	Physicians (n=24)	Business Owners (n=13)	P- Value	
% Non-Compliance	36.4%	16.7%	46.2%	0.116	
1-Year Freedom from Any-Treated Rejection	90.9%	87.5%	100.0%	0.361	
1-Year Freedom from Acute Cellular Rejection	100.0%	91.7%	100.0%	0.533	
1-Year Freedom from Antibody- Mediated Rejection	100.0%	100.0%	100.0%	1.000	
1-Year Freedom from Infection	60.0%	52.2%	46.2%	0.860	
5-Year Survival	72.7%	83.3%	92.3%	0.706	
5-Year Freedom from CAV	72.7%	79.2%	84.6%	0.464	
5-Year Freedom from NF-MACE*	72.7%	100.0%	69.2%	0.023	
*Business Owners vs Physicians, p=0.003, Teachers vs Physicians, p=0.007					

Results Summary

- There was no significant difference in 1-yr rejection, 5-yr survival or freedom from CAV among all groups.
- Numerically, military personnel did better in all outcomes except 5-yr freedom from NF-MACE.
- Teachers and business owners had a significantly reduced 5-yr freedom from NF-MACE vs. physicians (p=0.023, see table).
- There was no difference in compliance between professions.

business owners (n=13).

- Endpoints included:
 - 1-yr freedom from rejection and infection
 - 5-yr survival
 - 5-yr freedom from cardiac allograft vasculopathy(CAV) (angiographic stenosis ≥ 30%)
 - 5-yr freedom from nonfatal major adverse cardiac events (NF-MACE: myocardial infarction, new congestive heart failure, percutaneous coronary intervention, implantable cardioverter defibrillator/pacemaker implant, stroke)
- Compliance was assessed (cancelled or no-show appointments, lost to follow-up).

Conclusion

- OCC appears not to affect most outcomes or compliance following HTx.
- Military personnel may have better outcome.
- Further investigation into teachers and business owners having less freedom from NF-MACE is warranted but other variables may be important.

Author Disclosures

T. Kao: None. **A. Velleca:** None. **J. Patel:** G; C; Alexion, Pfizer, Alnylam. O; C; Therakos. **M. Kittleson:** None. **L. Czer:** G; C; St. Jude Medical. **S. Dimbil:** None. **R. Levine:** None. **A. Sanford:** None. **B. Kearney:** None. **E. Kransdorf:** None. **D. Chang:** G; C; Mesoblast, Amgen. S; C; Abbott Laboratories, AbbVie, Repligen. **J. Kobashigawa:** G; C; CareDx, Sanofi, CSL Behring.